Soliqua

Active Ingredient(s): Insulin Glargine + Lixisenatide
FDA Approved: * November 21, 2016
Pharm Company: * SANOFI AVENTIS US
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Soliqua Overview

Lixisenatide (trade name Lyxumia in the Europe and Adlyxin in the U.S.) is a once-daily injectable GLP-1 receptor agonist for the treatment of diabetes type II. Contents 1 Medical use 2 Adverse effects 3 Mechanism of action 4 Chemistry 5 History 6 References Medical use Lixisenatide is used as adjunct to diet and exercise to treat diabetes type II.[1] In Europe, its use is limited to complementing insulin therapy.[2] It is provided in an autoinjector containing fourteen doses and ...

Read more Soliqua Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lixisenatide

Recent Soliqua Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Insulin Glargine + Lixisenatide
  • Injection: 100units + 33mcg
  • Solution: 300 Units/3ml + 99mcg/3ml (100 Units/ml + 33mcg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (6 results)